Simple algorithm derived from a geno-/phenotypic database to predict HIV-1 protease inhibitor resistance

AIDS

Volumn 14, Issue 12, 2000, Pages 1731-1738

  Schmidt, Barbara ^a   Walter, Hauke ^a   Moschik, Brigitte ^a   Paatz, Christiane ^a   Van Vaerenbergh, Kristien ^a   Vandamme, Anne Mieke ^a   Schmitt, Matthias ^b   Harrer, Thomas ^b   Überla, Klaus ^c   Korn, Klaus ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^c UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Antiretroviral therapy; Cross resistance; HIV; Protease inhibitors; Resistance

Indexed keywords

INDINAVIR; NELFINAVIR; PROTEINASE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; VIRUS RNA;

ALGORITHM; ARTICLE; CROSS RESISTANCE; DATA BASE; DRUG RESISTANCE; DRUG SENSITIVITY; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ALGORITHMS; DATABASES, FACTUAL; DRUG RESISTANCE, MICROBIAL; GENOTYPE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; PHENOTYPE; POINT MUTATION; SENSITIVITY AND SPECIFICITY;

EID: 0033831385     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200008180-00007     Document Type: Article

References (29)

1. Changing patterns of mortality across Europe in patients infected with HIV-1
2. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators
3. HIV-protease inhibitors
4. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease
5. Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor
6. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors
7. HIV protease genotype and viral sensitivity to HIV protease inhibitors following saquinavir therapy
8. Constrained evolution of human immunodeficiency virus type 1 protease during sequential therapy with two distinct protease inhibitors
9. Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development
10. Anti-human immunodeficiency virus drug combination strategies
11. HIV treatment failure: Testing for HIV resistance in clinical practice
12. Mutations in retroviral genes associated with drug resistance: 1999-2000 update
13. Recombinant virus assay: A rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates
14. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs
15. Rapid, phenotypic HIV-1 drug sensitivity assay for protease and reverse transcriptase inhibitors
16. Activity of a ritonavir plus saquinavir-containing regimen in patients with virologic evidence of indinavir or ritonavir failure
17. Human immunodeficiency virus type 1 protease genotypes and in vitro protease inhibitor susceptibilities of isolates from individuals who were switched to other protease inhibitors after long-term saquinavir treatment
18. Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538)
19. Genotypic changes in human immunodeficiency virus type 1 associated with loss of suppression of plasma viral RNA levels in subjects treated with ritonavir (Norvir) monotherapy
20. Resistance and cross-resistance with saquinavir and other HIV protease inhibitors: Theory and practice
21. Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors
22. Neutralization sensitivity of cell culture-passaged simian immunodeficiency virus
23. Drug-resistance genotyping in HIV-1 therapy: The VIRADAPT randomised controlled trial
24. Nelfinavir. A review of its therapeutic efficacy in HIV infection
25. A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection
26. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir
27. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites
28. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: Phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients
29. Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo